Elez, E. (Elena)

Filtering

20231

Settings

Author search.filters.isAuthorOfPublication.0dee1585-d054-419a-9d28-adf3ec98de50

Search Results

Now showing 1 - 1 of 1
  • Thumbnail Image
    Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer
    (2023) Yamaguchi, K. (Kensei); Loupakis, F. (Fotios); Fakih, M. (Marwan); Kobayashi, K. (Kojiro); Grothey, A. (Axel); Ciardiello, F. (Fortunato); Saxena, F. (Kapil); Di-Bartolomeo, M. (Maria); Masuishi, T. (Toshiki); Raghav, K. (Kanwal); Yoshino, T. (Takayuki); Meinhardt, G. (Gerold); Kawakami, H. (Hisato); Nishina, T. (Tomohiro); Siena, S. (Salvatore); Elez, E. (Elena); Rodríguez-Rodríguez, J. (Javier); Bako, E. (Emarjola); Wainberg, Z. (Zev); Okuda, Y. (Yasuyuki)
    DESTINY-CRC01 (NCT03384940) was a multicenter, open-label, phase 2 trial assessing the efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients with HER2-expressing metastatic colorectal cancer (mCRC) that progressed after >= 2 prior regimens; results of the primary analysis are published. Patients received T-DXd 6.4mg/kg every 3 weeks and were assigned to either: cohort A (HER2-positive, immunohistochemistry [IHC] 3+ or IHC 2+/in situ hybridization [ISH]+), cohort B (IHC 2+/ISH-), or cohort C (IHC 1+). Primary endpoint was objective response rate (ORR) by independent central review in cohort A. Secondary endpoints included ORR (cohorts B and C), duration of response, disease control rate, progression-free survival, overall survival, pharmacokinetics, and safety of T-DXd. 86 patients were enrolled (53 in cohort A, 15 in cohort B, and 18 in cohort C). Results of the primary analysis are published, reporting an ORR of 45.3% in cohort A. Here, we report the final results. No responses occurred in cohorts B or C. Median progression-free survival, overall survival, and duration of response were 6.9, 15.5, and 7.0 months, respectively. Overall serum exposure (cycle 1) of T-DXd, total anti-HER2 antibody, and DXd were similar regardless of HER2 status. Most common grade >= 3 treatment-emergent adverse events were decreased neutrophil count and anemia. Adjudicated drug-related interstitial lung disease/pneumonitis occurred in 8 patients (9.3%). These findings support the continued exploration of T-DXd in HER2-positive mCRC.